Literature DB >> 32558345

miR-744-5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer.

Lai-Gang Zhao1, Jiao Wang1, Jin Li1, Qin-Fen Li1.   

Abstract

miR-744-5p has been demonstrated to play an important role in cancer progression. However, the functions of miR-744-5p in epithelial ovarian cancer (EOC) are not well clarified. In this study, our aim was to investigate the role of miR-744-5p and its underlying molecular mechanism in cell progression of EOC. EOC clinical tissues and matched adjacent ovarian epithelial tissues were collected from 18 patients. Tissues and cell lines were analyzed by qPCR or Western blot to investigate the expression of miR-744-5p and ARF1 in EOC. Cell proliferative capacity was assessed by CCK8 and colony formation assays. Wound healing and transwell assays were performed to evaluate cell migration and invasion. The potential binding relation between miR-744-5p and IRF1 was demonstrated by dual luciferase report assay. The results showed that expression of miR-744-5p was low in EOC clinical tissues and cells. Overexpression of miR-744-5p inhibited proliferation, migration, and invasion of EOC cells. Further mechanistic study identified that ARF1 is a target of miR-744-5p, which is negatively correlated with the expression of miR-744-5p, and overexpression of ARF1 could reverse the inhibition of miR-744-5p on the proliferation, migration, and invasion of EOC cells. Taken together, our results indicated that miR-744-5p attenuated EOC progression via targeting IRF1, providing potential guidance for the clinical treatment of ovarian cancer.
© 2020 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  IRF1; epithelial ovarian cancer; invasion; miR-744-5p; proliferation

Mesh:

Substances:

Year:  2020        PMID: 32558345     DOI: 10.1002/kjm2.12253

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  6 in total

1.  miR-744-5p suppresses tumor proliferation and metastasis by targeting transforming growth factor-beta 1 (TGF-β1) in hepatocellular carcinoma (HCC).

Authors:  Weifeng Huang; Qingsong Chen; Jiangweng Dai; Yuke Zhang; Yan Yi; Xufu Wei; Zhongjun Wu
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  MicroRNA-744-5p suppresses tumorigenesis and metastasis of osteosarcoma through the p38 mitogen-activated protein kinases pathway by targeting transforming growth factor-beta 1.

Authors:  Haofeng Liang; Lin Li; Shuang Zhu; Jianye Tan; Bingsheng Yang; Xiaoping Wang; Guofeng Wu; Chao Xie; Lutao Li; Zhengwei Liu; Yucong Li; Haoqiang Song; Guoli Chen; Lijun Lin
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Mesenchymal stem cell-derived extracellular vesicles prevent glioma by blocking M2 polarization of macrophages through a miR-744-5p/TGFB1-dependent mechanism.

Authors:  Ling Liu; Meixiong Cheng; Tian Zhang; Yong Chen; Yaqiu Wu; Qi Wang
Journal:  Cell Biol Toxicol       Date:  2022-01-03       Impact factor: 6.819

4.  LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis.

Authors:  Yang Shen; Mengmeng Lv; Yichen Fang; Jin Lu; Yuzhong Wu
Journal:  J Ovarian Res       Date:  2021-11-17       Impact factor: 4.234

5.  The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.

Authors:  Paweł Robak; Izabela Dróżdż; Dariusz Jarych; Damian Mikulski; Edyta Węgłowska; Monika Siemieniuk-Ryś; Małgorzata Misiewicz; Konrad Stawiski; Wojciech Fendler; Janusz Szemraj; Piotr Smolewski; Tadeusz Robak
Journal:  Cancers (Basel)       Date:  2020-09-09       Impact factor: 6.639

6.  Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.

Authors:  Przemysław A Stempor; Dror Avni; Raya Leibowitz; Yechezkel Sidi; Maria Stępień; Tomasz Dzieciątkowski; Paula Dobosz
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.